Top

Published in:

Open Access 01-12-2009 | Research

Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells

Authors: Martin Michaelis, Denise Klassert, Susanne Barth, Tatyana Suhan, Rainer Breitling, Bernd Mayer, Nora Hinsch, Hans W Doerr, Jaroslav Cinatl, Jindrich Cinatl jr

Published in: Molecular Cancer | Issue 1/2009

Abstract

Background

Chemoresistance acquisition may influence cancer cell biology. Here, bioinformatics analysis of gene expression data was used to identify chemoresistance-associated changes in neuroblastoma biology.

Results

Bioinformatics analysis of gene expression data revealed that expression of angiogenesis-associated genes significantly differs between chemosensitive and chemoresistant neuroblastoma cells. A subsequent systematic analysis of a panel of 14 chemosensitive and chemoresistant neuroblastoma cell lines in vitro and in animal experiments indicated a consistent shift to a more pro-angiogenic phenotype in chemoresistant neuroblastoma cells. The molecular mechanims underlying increased pro-angiogenic activity of neuroblastoma cells are individual and differ between the investigated chemoresistant cell lines. Treatment of animals carrying doxorubicin-resistant neuroblastoma xenografts with doxorubicin, a cytotoxic drug known to exert anti-angiogenic activity, resulted in decreased tumour vessel formation and growth indicating chemoresistance-associated enhanced pro-angiogenic activity to be relevant for tumour progression and to represent a potential therapeutic target.

Conclusion

A bioinformatics approach allowed to identify a relevant chemoresistance-associated shift in neuroblastoma cell biology. The chemoresistance-associated enhanced pro-angiogenic activity observed in neuroblastoma cells is relevant for tumour progression and represents a potential therapeutic target.

Available only for authorised users

Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-2120. 10.1016/S0140-6736(07)60983-0CrossRefPubMed

Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol. 1999, 17: 2264-2279.PubMed

Goldsmith KC, Hogarty MD: Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett. 2005, 228: 133-141. 10.1016/j.canlet.2005.01.048CrossRefPubMed

Shah AN, Gallick GE: Src, chemoresistance and epithelial to mesenchymal transition: are they related?. Anticancer Drugs. 2007, 18: 371-375. 10.1097/CAD.0b013e32801265d7CrossRefPubMed

Ogbomo H, Michaelis M, Klassert D, Doerr HW, Cinatl J: Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia. 2008, 10: 1402-1410.PubMedCentralCrossRefPubMed

Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C, Zhu Z, Xiong D: Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia. 2008, 10: 1275-1284.PubMedCentralCrossRefPubMed

Blaheta RA, Daher FH, Michaelis M, Hasenberg C, Weich EM, Jonas D, Kotchetkov R, Doerr HW, Cinatl J: Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer. 2006, 6: 294- 10.1186/1471-2407-6-294PubMedCentralCrossRefPubMed

Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW, Cinatl J: Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer. 2007, 96: 1699-1706. 10.1038/sj.bjc.6603777PubMedCentralCrossRefPubMed

Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J: Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol. 2006, 28: 439-446.PubMed

10.

Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T: One, two, three--p53, p63, p73 and chemosensitivity. Drug Resist Updat. 2006, 9: 288-306. 10.1016/j.drup.2007.01.001CrossRefPubMed

11.

Fernandez-Luna JL: Regulation of pro-apoptotic BH3-only proteins and its contribution to cancer progression and chemoresistance. Cell Signal. 2008, 20: 1921-1926. 10.1016/j.cellsig.2008.04.015CrossRefPubMed

12.

Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19: 185-193. 10.1093/bioinformatics/19.2.185CrossRefPubMed

13.

Mi H, Guo N, Kejariwal A, Thomas PD: PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 2007, D247-52. 35 Database.

14.

Cho RJ, Campbell MJ: Transcription, genomes, function. Trends Genet. 2000, 16: 409-415. 10.1016/S0168-9525(00)02065-5CrossRefPubMed

15.

Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995, 57: 289-300.

16.

Cinatl J, Vogel JU, Cinatl J, Weber B, Rabenau H, Novak M, Kornhuber B, Doerr HW: Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer. 1996, 65: 90-96. 10.1002/(SICI)1097-0215(19960103)65:1<90::AID-IJC16>3.0.CO;2-MCrossRefPubMed

17.

Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T, Cinatl J: Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer. 2003, 104: 36-43. 10.1002/ijc.10917CrossRefPubMed

18.

Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J, Cinatl J: Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol. 2005, 27: 1029-1037.PubMed

19.

Michaelis M, Cinatl J, Anand P, Rothweiler F, Kotchetkov R, von Deimling A, Doerr HW, Shogen K, Cinatl J: Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett. 2007, 250: 107-116. 10.1016/j.canlet.2006.09.018CrossRefPubMed

20.

Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J: Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res. 2008, 14: 6531-6537. 10.1158/1078-0432.CCR-08-0821CrossRefPubMed

21.

Cinatl J, Michaelis M, Driever PH, Cinatl J, Hrabeta J, Suhan T, Doerr HW, Vogel JU: Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia. 2004, 6: 725-735. 10.1593/neo.04265PubMedCentralCrossRefPubMed

22.

Cinatl J, Margraf S, Vogel JU, Scholz M, Cinatl J, Doerr HW: Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells. J Immunol. 2001, 167: 1900-1908.CrossRefPubMed

23.

Papoutsi M, Sleeman JP, Wilting J: Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane. Microsc Res Tech. 2001, 55: 100-107. 10.1002/jemt.1161CrossRefPubMed

24.

Schadendorf D, Kern MA, Artuc M, Pahl HL, Rosenbach T, Fichtner I, Nürnberg W, Stüting S, von Stebut E, Worm M, Makki A, Jurgovsky K, Kolde G, Henz BM: Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol. 1996, 135: 1889-1898. 10.1083/jcb.135.6.1889CrossRefPubMed

25.

Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, Bibby M: Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004, 40: 298-307. 10.1016/j.ejca.2003.10.011CrossRefPubMed

26.

Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998, 273: 13313-13316. 10.1074/jbc.273.21.13313CrossRefPubMed

27.

Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999, 247: 495-504. 10.1006/excr.1998.4359CrossRefPubMed

28.

Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L, Werz O, Eikel D, Zörnig M, Nau H, Fleming I, Doerr HW, Cinatl J: Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ. 2006, 13: 446-453. 10.1038/sj.cdd.4401759CrossRefPubMed

29.

Zachary I: VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans. 2003, 31: 1171-1177. 10.1042/BST0311171CrossRefPubMed

30.

Angelo LS, Kurzrock R: Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res. 2007, 13: 2825-2830. 10.1158/1078-0432.CCR-06-2416CrossRefPubMed

31.

Jiang BH, Liu LZ: AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 2008, 8: 19-26. 10.2174/156800908783497122CrossRefPubMed

32.

Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 2000, 6: 1900-1908.PubMed

33.

Rössler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka-Süss R, Niemeyer CM, Vassal G: Angiogenesis as a target in neuroblastoma. Eur J Cancer. 2008, 44: 1645-1656. 10.1016/j.ejca.2008.05.015CrossRefPubMed

34.

Tsuchida R, Das B, Yeger H, Koren G, Shibuya M, Thorner PS, Baruchel S, Malkin D: Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene. 2008, 27: 3923-3934. 10.1038/onc.2008.38CrossRefPubMed

35.

Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takihara K, Ziche M, Rofstad EK, Schweigerer L, Fotsis T: N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene. 2002, 21: 3552-3561. 10.1038/sj.onc.1205440CrossRefPubMed

36.

Schramm A, von Schuetz V, Christiansen H, Havers W, Papoutsi M, Wilting J, Schweigerer L: High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. Oncogene. 2005, 24: 680-687. 10.1038/sj.onc.1208087CrossRefPubMed

37.

Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH: N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene. 2008, 27: 3999-4007. 10.1038/onc.2008.15PubMedCentralCrossRefPubMed

38.

Teodoro JG, Evans SK, Green MR: Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med. 2007, 85: 1175-1186. 10.1007/s00109-007-0221-2CrossRefPubMed

39.

Amoh Y, Li L, Yang M, Jiang P, Moossa AR, Katsuoka K, Hoffman RM: Hair follicle-derived blood vessels vascularize tumors in skin and are inhibited by doxorubicin. Cancer Res. 2005, 65: 2337-2343. 10.1158/0008-5472.CAN-04-3857CrossRefPubMed

40.

Amoh Y, Li L, Katsuoka K, Hoffman RM: Chemotherapy targets the hair-follicle vascular network but not the stem cells. J Invest Dermatol. 2007, 127: 11-15. 10.1038/sj.jid.5700486CrossRefPubMed

41.

Gustafson DL, Rastatter JC, Colombo T, Long ME: Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci. 2002, 91: 1488-1501. 10.1002/jps.10161CrossRefPubMed

42.

Gustafson DL, Merz AL, Long ME: Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett. 2005, 220: 161-169. 10.1016/j.canlet.2004.09.007CrossRefPubMed

43.

Breistøl K, Hendriks HR, Fodstad O: Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. Eur J Cancer. 1999, 35: 1143-1149. 10.1016/S0959-8049(99)00074-XCrossRefPubMed

44.

Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, McGary EC, Ananthaswamy HN, Price JE, Bar-Eli M: Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004, 22: 2092-2100. 10.1200/JCO.2004.11.070CrossRefPubMed

45.

Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, Baker SD, Bhujwalla ZM, Artemov D: Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther. 2007, 6: 891-897. 10.1158/1535-7163.MCT-06-0125PubMedCentralCrossRefPubMed

46.

Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE. 2008, 3: e3077- 10.1371/journal.pone.0003077PubMedCentralCrossRefPubMed

47.

Mita AC, Mita MM, Nawrocki ST, Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008, 14: 5000-5005. 10.1158/1078-0432.CCR-08-0746CrossRefPubMed

48.

Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001, 91: 2026-2032. 10.1002/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO;2-ECrossRefPubMed

49.

Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC: Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003, 63: 7724-7732.PubMed

50.

Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC, Zhu YB, Zou B, Ng SS, Jiang SH, Xia HH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC: Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology. 2005, 128: 361-375. 10.1053/j.gastro.2004.11.058CrossRefPubMed

51.

Zhao Y, Shen S, Guo J, Chen H, Greenblatt DY, Kleeff J, Liao Q, Chen G, Friess H, Leung PS: Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res. 2006, 136: 325-335. 10.1016/j.jss.2006.06.031CrossRefPubMed

52.

Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, Bojar H, Tannapfel A, Hengge UR: ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol. 2007, 127: 2207-2215. 10.1038/sj.jid.5700870CrossRefPubMed

53.

Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC: Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008, 68: 6109-6117. 10.1158/0008-5472.CAN-08-0579PubMedCentralCrossRefPubMed

54.

Carroll VA, Ashcroft M: Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res. 2008, 68: 545-552. 10.1158/0008-5472.CAN-06-4738CrossRefPubMed

55.

West KA, Castillo SS, Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002, 5: 234-248. 10.1016/S1368-7646(02)00120-6CrossRefPubMed

56.

Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E, D'Atri S: AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol. 2008, 74: 173-183. 10.1124/mol.107.044743CrossRefPubMed

57.

Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E: Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008, 13: 259-271. 10.1007/s10495-007-0165-6CrossRefPubMed

58.

Mitsiades CS, Mitsiades N, Koutsilieris M: The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets. 2004, 4: 235-256. 10.2174/1568009043333032CrossRefPubMed

59.

Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006, 25: 6986-6996. 10.1038/sj.onc.1209685CrossRefPubMed

60.

Xia C, Meng Q, Cao Z, Shi X, Jiang BH: Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol. 2006, 209: 56-66. 10.1002/jcp.20707CrossRefPubMed

61.

Anfosso L, Efferth T, Albini A, Pfeffer U: Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 2006, 6: 269-278.PubMed

62.

Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E: Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer. 2008, 123: 2031-2040. 10.1002/ijc.23732PubMedCentralCrossRefPubMed

63.

Zaghloul N, Hernandez SL, Bae JO, Huang J, Fisher JC, Lee A, Kadenhe-Chiweshe A, Kandel JJ, Yamashiro DJ: Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol. 2009, 34: 401-407.PubMedCentralPubMed

64.

Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS: Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res. 2008, 14: 1529-1539. 10.1158/1078-0432.CCR-07-4126CrossRefPubMed

65.

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056/NEJMoa072113CrossRefPubMed

66.

Meitar D, Crawford SE, Rademaker AW, Cohn SL: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 1996, 14: 405-414.PubMed

67.

Ribatti D, Surico G, Vacca A, De Leonardis F, Lastilla G, Montaldo PG, Rigillo N, Ponzoni M: Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 2001, 68: 1161-1168. 10.1016/S0024-3205(00)01030-4CrossRefPubMed

68.

Katzenstein HM, Cohn SL, Crawford S, Meitar D: Angiogenesis in neuroblastoma. J Clin Oncol. 2000, 18: 2789-2791.PubMed

69.

Cañete A, Navarro S, Bermúdez J, Pellín A, Castel V, Llombart-Bosch A: Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol. 2000, 18: 27-34.PubMed

70.

Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol. 2006, 24: 5070-5078. 10.1200/JCO.2006.06.1879CrossRefPubMed

71.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC: Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006, 98: 1193-1203. 10.1093/jnci/djj330CrossRefPubMed

Title: Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells
Authors: Martin Michaelis
Denise Klassert
Susanne Barth
Tatyana Suhan
Rainer Breitling
Bernd Mayer
Nora Hinsch
Hans W Doerr
Jaroslav Cinatl
Jindrich Cinatl jr
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-8-80

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma

Identification of small molecule compounds that inhibit the HIF-1 signaling pathway

Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2

Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients

iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer